Ergomed (AIM:ERGO) - Cotización, noticias y análisis

Resumen de acción ERGO

Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. Saber más

Análisis fundamental de ERGO
Puntuación del snowflake
Valoración	0/6
Crecimiento futuro	3/6
Rendimiento pasado	3/6
Salud financiera	6/6
Dividendos	0/6

Recompensas

Se prevé un crecimiento anual de los beneficios de 14.17%

Los beneficios aumentaron un 12.3% el pasado año

Análisis de riesgos

Volatilidad del precio de la acción en los últimos 3 meses

Los accionistas han sido diluidos en el último año

Competidores de Ergomed plc

hVIVO

AIM:HVO

UK£172.8m

C4X Discovery Holdings

AIM:C4XD

UK£30.3m

Genus

LSE:GNS

UK£1.1b

Bioventix

AIM:BVXP

UK£195.7m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Ergomed
Precios históricos de las acciones
Precio actual de la acción	UK£13.46
Máximo en las últimas 52 semanas	UK£13.80
Mínimo de 52 semanas	UK£8.95
Beta	0.79
1Cambio en 1 mes	0.90%
Variación en 3 meses	21.26%
Cambio de 1 año	3.54%
3Variación en 3 años	67.41%
Variación en 5 años	812.54%
Variación desde la OPV	728.31%

Noticias y actualizaciones recientes

Recent updates

If You Had Bought Ergomed (LON:ERGO) Stock Five Years Ago, You Could Pocket A 643% Gain Today

Feb 22

Has Ergomed plc's (LON:ERGO) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Jan 18

Ergomed plc's (LON:ERGO) Intrinsic Value Is Potentially 20% Below Its Share Price

Dec 13

We Think Ergomed's (LON:ERGO) Statutory Profit Might Understate Its Earnings Potential

Nov 23

Rentabilidad de los accionistas

	ERGO	GB Life Sciences	Mercado GB
7D	0.1%	-7.2%	-0.3%
1Y	3.5%	-32.1%	6.1%

Rentabilidad vs. Industria: ERGO superó a la industria UK Life Sciences, que obtuvo un rendimiento del -32.1% el año pasado.

Rentabilidad vs. Mercado: ERGO superó al mercado UK, que obtuvo un rendimiento del 6.1% el año pasado.

Volatilidad de los precios

Is ERGO's price volatile compared to industry and market?
ERGO volatility
ERGO Average Weekly Movement	8.1%
Life Sciences Industry Average Movement	5.6%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Precio estable de las acciones: El precio de las acciones de ERGO ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ERGO(8%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de UK.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1997	1,400	n/a	www.ergomedplc.com

Resumen de fundamentos de Ergomed plc

¿Cómo se comparan los beneficios e ingresos de Ergomed con su capitalización de mercado?
Estadísticas fundamentales de ERGO
Capitalización bursátil	UK£701.05m
Beneficios(TTM)	UK£15.00m
Ingresos (TTM)	UK£152.09m

46.7x

Ratio precio-beneficio (PE)

4.6x

Ratio precio-ventas (PS)

¿Está ERGO sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ERGO
Ingresos	UK£152.09m
Coste de los ingresos	UK£68.82m
Beneficio bruto	UK£83.27m
Otros gastos	UK£68.27m
Beneficios	UK£15.00m

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	0.29
Margen bruto	54.75%
Margen de beneficio neto	9.86%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado ERGO a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción ERGO

Recompensas

Análisis de riesgos

Competidores de Ergomed plc

AIM:HVO

UK£172.8m

AIM:C4XD

UK£30.3m

LSE:GNS

UK£1.1b

AIM:BVXP

UK£195.7m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Recent updates

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Now 20% undervalued after recent price drop

Is It Time To Consider Buying Ergomed plc (LON:ERGO)?

Ergomed plc Provides Earnings Forecast for the Full Year 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ergomed plc, Annual General Meeting, Jun 22, 2023

At UK£9.74, Is Ergomed plc (LON:ERGO) Worth Looking At Closely?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Ergomed plc to Report Fiscal Year 2022 Results on Mar 21, 2023

High number of new and inexperienced directors

Ergomed plc Announces Board Changes, Effective 3 February 2023

Ergomed plc Announces Executive Changes

Ergomed plc Announces Directorate Changes

Ergomed Announces Two Senior Appointments to its Executive Team

Ergomed Strengthens Executive Management Team

Ergomed Strengthens Executive Management Team

Ergomed plc (LON:ERGO) Shares Could Be 21% Below Their Intrinsic Value Estimate

First half 2022 earnings released: EPS: UK£0.15 (vs UK£0.14 in 1H 2021)

Ergomed plc to Report First Half, 2022 Results on Sep 27, 2022

Investor sentiment improved over the past week

Should You Be Adding Ergomed (LON:ERGO) To Your Watchlist Today?

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc Appoints Anne Whitaker as Independent Non-Executive Director

Full year 2021 earnings: EPS misses analyst expectations

Ergomed plc, Annual General Meeting, Jun 10, 2022

Consensus EPS estimates increase by 11%

Consensus forecasts updated

Less than half of directors are independent

Now 21% undervalued

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Full year 2021 earnings: EPS misses analyst expectations

Does Ergomed (LON:ERGO) Deserve A Spot On Your Watchlist?

John Dawson, Cbe Joins the Board of Ergomed plc as Independent Non-Executive Director and Chair of the Audit Committee

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc to Report Fiscal Year 2021 Results on Mar 29, 2022

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

Ergomed plc (AIM:ERGO) acquired Adamas Consulting Ltd. at an enterprise value of £24.2 million.

Ergomed plc Provides Revenue Guidance for the Year Ended 31 December 2021

Investor sentiment deteriorated over the past week

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Ergomed (LON:ERGO) Passed With Ease

First half 2021 earnings released: EPS UK£0.14 (vs UK£0.089 in 1H 2020)

Calculating The Intrinsic Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out Ergomed (LON:ERGO) Before It's Too Late

Getting In Cheap On Ergomed plc (LON:ERGO) Might Be Difficult

Ergomed plc (LON:ERGO) Shares Could Be 31% Above Their Intrinsic Value Estimate

Price target increased to UK£13.65

Non-Executive Director has left the company

Investor sentiment improved over the past week

Do Ergomed's (LON:ERGO) Earnings Warrant Your Attention?

Full year 2020 earnings released